Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04867980 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

A Phase 1 study, sponsored by Acerta Pharma.

Completed
Registry status
Phase 1
Development phase
48
Enrollment target

NCT04867980: Completed Phase 1 study, sponsored by Acerta Pharma.

NCT04867980 is a Phase 1 study that has completed, run by Acerta Pharma. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04867980, a Phase 1 study, has completed, sponsored by Acerta Pharma.

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target

Study Summary

This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).

Interventions

  • DRUG Placebo
  • DRUG ACP-196
  • DRUG Moxifloxacin 400 mg

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2016-04-01
Est. Completion 2016-05-09
Phase Phase 1
Acerta Pharma

38 total trials

What the finished NCT04867980 record still lists

NCT04867980 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT04867980 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04867980 about?

NCT04867980 is a clinical study titled "A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants". This study is to evaluate the effects of single therapeutic and supratherapeutic oral doses of ACP-196 on the heart rate-corrected QT interval using Fridericia's formula (QTcF).

What is the current status of trial NCT04867980?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-04-01. Estimated completion is 2016-05-09.

What interventions are being tested in trial NCT04867980?

The interventions under investigation include: Placebo (DRUG), ACP-196 (DRUG), Moxifloxacin 400 mg (DRUG).

Who is sponsoring clinical trial NCT04867980?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04867980's enrollment target sits among peer trials

48 1025th of 2000 higher than 948 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04867980, the US trial registry maintained by the National Library of Medicine. NCT04867980 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.